Figure 1 from Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T
Year: 2024
Type: other
Abstract: Study design and in vitro responsiveness of PBMCs from patients with mCRPC to PRR agonist prior to sip-T treatment. A, Banked pretreatment PBMCs from the PRIME sip-T discovery cohort (n = 106) or KCI validation cohort (n = 28) were subjected to DNA isolation, flow cytometry, and/or testing in an in vitro stimulation assay. Two hundred thousand PBMCs per well were plated and treated with no stimulation (mock) or stimulation (stim) with TLR1/2 (PAM3CSK4), TLR4 (LPS), MDA5 (Poly I:C-LyoVec), or T-cell [anti (α)-CD3/28 antibodies] after 24 hours of culture. B–D, Supernatant cytokine release was measured after in vitro stimulation. B, Principal component analyses colored by treatment using raw MFI values for each analyte, each data point represents a single patient. C, Box and whisker plots (Boxes: median ± 25%–75% quartiles, whiskers = range) of fold mock MFI values for each cytokine in the PRIME study (n = 106), each data point represents a single patient. D, Heatmaps of log (fold mock control) values are shown for the PRIME and KCI (validation) cohorts; asterisks denote FDR adjusted Q < 0.05 using one sample t test vs. 0 (no induction). MFI, mean fluorescence intensity.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4403547125